* Intra-Cellular Therapies Inc ITCI.OQ reported a
quarterly
adjusted loss of 30 cents per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -45 cents. The mean expectation of
fifteen analysts for the quarter was for a loss of 44 cents per
share. Wall Street expected results to range from -58 cents
to -34 cents per share.
* Revenue rose 50.3% to $132.10 million from a year ago;
analysts
expected $135.67 million.
* Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 30 cents.
* The company reported a quarterly loss of $28.58 million.
* Intra-Cellular Therapies Inc shares had risen by 2.3% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months.
* In the last 30 days, four analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Intra-Cellular
Therapies Inc is $82.00
This summary was machine generated from LSEG data February 23 at
03:04 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.44 -0.30 Beat
Sep. 30 2023 -0.57 -0.25 Beat
Jun. 30 2023 -0.59 -0.45 Beat
Mar. 31 2023 -0.61 -0.46 Beat